• Mutation; HGNC; HGNC:7773; NF2; Simple; c.1575-1G>A; ClinVar=VCV001285395; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=11836557).
  

PubMed=11836557; DOI=10.3892/ijo.20.3.475
Hung G., Li X.-K., Faudoa R., Xeu Z., Kluwe L., Rhim J.S., Slattery W., Lim D.J.
Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.
Int. J. Oncol. 20:475-482(2002)

PubMed=17304235; DOI=10.1038/sj.cgt.7701037
Prabhakar S., Messerli S.M., Stemmer-Rachamimov A.O., Liu T.-C., Rabkin S.D., Martuza R.L., Breakefield X.O.
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.
Cancer Gene Ther. 14:460-467(2007)

PubMed=17868749; DOI=10.1016/j.mrfmmm.2007.07.015; PMCID=PMC2233940
Lepont P., Stickney J.T., Foster L.A., Meng J.-J., Hennigan R.F., Ip W.
Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Mutat. Res. 637:142-151(2008)

PubMed=28469964; PMCID=PMC5411799
Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R., Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C., Field J.
Comprehensive pharmacological profiling of neurofibromatosis cell lines.
Am. J. Cancer Res. 7:923-934(2017)